Resveratrol Bioavailability After Oral Administration: A Meta-Analysis of Clinical Trial Data.

Autor: Szymkowiak I; Curtis Health Caps S.A., Przezmierowo, Poland.; Department of Toxicology, Poznan University of Medical Sciences, Poznan, Poland., Marcinkowska J; Department of Computer Science and Statistics, Poznan University of Medical Science, Poznan, Poland., Kucinska M; Department of Toxicology, Poznan University of Medical Sciences, Poznan, Poland., Regulski M; Curtis Health Caps S.A., Przezmierowo, Poland., Murias M; Department of Toxicology, Poznan University of Medical Sciences, Poznan, Poland.
Jazyk: angličtina
Zdroj: Phytotherapy research : PTR [Phytother Res] 2024 Nov 18. Date of Electronic Publication: 2024 Nov 18.
DOI: 10.1002/ptr.8379
Abstrakt: Annually, a growing body of studies substantiates the health advantages of polyphenolic compounds, yet their practical application is constrained by swift metabolism and low bioavailability. Resveratrol, a stilbene derivative showcasing typical polyphenolic traits, is particularly noteworthy. Despite abundant bioavailability data from in vitro and animal studies, applying these findings to humans demands nuanced consideration. The objective of this article is to conduct a meta-analysis on clinical trial data, systematically assessing the oral bioavailability of resveratrol and deriving meaningful insights into its efficacy in humans. To achieve this goal, we thoroughly examined publications across five major global databases: PubMed, Cochrane Library, Scopus, Embase, and Science Direct. The study exclusively included clinical trials involving healthy adults, where pharmacokinetic parameters were measured following the oral administration of at least one dose of resveratrol as a single preparation. For the meta-analysis data extraction, the mean score and standard deviation (SD) were included. Heterogeneity, degree of inconsistency between studies, and meta-regression were assessed. From these searches, we scrutinized data from 84 oral administrations encompassing nine resveratrol doses ranging from 25 to 5000 mg. Our findings indicate a linear increase in the amount of free resveratrol entering the bloodstream with the administered dose, while T max values remain unaffected. The mean maximum plasma concentration of resveratrol (31.07 ng/mL) closely mirrors the mean C max observed in the group administered a medium resveratrol dose ranging from 100 to 500 mg (33.59 ng/mL). This similarity implies the appropriateness of employing these specific doses of resveratrol, taking into consideration both its bioavailability and very low risk of potential side effects. However, the analysis of available human oral bioavailability data is constrained by methodological inconsistencies prevalent in existing studies. The meta-analysis underscores substantial heterogeneity, underscoring the imperative for multiple studies to rectify this prevailing trend.
(© 2024 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: